Anti-inflammatory Effects of Ramipril In Experimentally Induced Rheumatoid Arthritis
Anti-inflammatory Effects of Ramipril
DOI:
https://doi.org/10.70284/njirm.v4i3.2170Keywords:
Anti-inflammatory agents, Adjuvant induced arthritis, Experimental rheumatoid arthritis,RamiprilAbstract
Objective: To evaluate anti-inflammatory effects of ramipril in experimentally induced rheumatoid arthritis (RA).Materials and Methods: Adjuvant induced arthritis model is used in this study.Albino-Wistar rats of either sex were used. Arthritis was induced by single intradermal injection of Freund’s complete adjuvant (FCA) suspended in oil inplantar region of right hind paw. Rats were divided in to three groups (n=8) namely disease control, standard and test group. Drug treatment was carried out for 21 days. Effect of test drug on acute inflammatory phase was evaluated on day 5 by assessing right hind paw edema. After 21 days animals were sacrificed and evaluated for left hind paw edema, weight changes, histo-pathological synovitis grading in left hind limbs and secondary lesion score.Results: Results showed that ramiprilsignificantly reduced right hind paw edema on day 5 (p<0.05). Ramipril also showed statistically significant weight gain (p<0.05), reduction of histo-pathological synovitis grade (p<0.05) as well as secondary lesion score (p<0.05).Conclusion:Our study suggests that ramiprilmay be used as an adjuvant anti-inflammatory agent in patients with RA. However this speculation needs to be confirmed clinically.
References
1. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1991;21(2 supplement 1):4–12.
2. Maya Buch. The etiology and pathogenesis of Rheumatoid Arthritis. Hospital Pharmacist. 2002;9:5-10.
3. Peter E. Lipsky. Rheumatoid arthritis. In: Fauci, Braunwald, Kasper, Hauser, Lango, Jaueson et al. Harrison’s Principles of Internal Medicine.17th ed. New York: McGraw-Hill. 2008: 2088-92.
4. Ruiz-Ortega, Marta, Lorenzo. Proinflammatory actions of angiotensins. Current Opinion in Nephrology & Hypertension.2001; 10(3): 321-329.
5. M. Ruiz-Ortega, O. Lorenzo, M. Rupérez. Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field. Hypertension. 2001; 38: 1382-1387.
6. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem Biophys Res Commun.1999; 257: 826-8.
7. Gunter Wolf, Ulrich Wenzel, Kevin D Burns. Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney International. 2002; 61: 1986–1995.
8. J R Lowe, J S Dixon, J A Guthrie. Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis. Ann Rheum Dis. 1986; 45: 921-924.
9. David A. Walsh, Takahiro Suzuki, Gregory A. Knock. AT1 receptor characteristics ofangiotensin analogue binding in human synovium. Br. J. Pharmacol.1994; 112: 435-442.
10. Martin MFR, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril a new treatment for rheumatoid arthritis? Lancet. 1984; 1: 1325-1328.
11. Bird HA, Le Gallez P, Dixon JS, Catalano MA, Traficante A, Liauw L, et al. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentropril; CGS-13945) in active rheumatoid arthritis. J Rheumatol. 1990; 17: 603–8.
12. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford). 2005; 44: 24–31.
13. Pearson C.M., Wood F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. General, clinical and pathological characteristics and modifying factors. Arthritis and Rheumatism. 1959;2:440-459.
14. Krenn V, Morawietz L, Haupl T. Grading of chronic synovitis- a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract. 2002;198(5):317-25.
15. Vogel HG. Adjuvant Arthritis in Rats. In Drug discovery & evaluation: Pharmacological assays. 3rded. New York: Springer – Verlag. 2008: 1162-1166.
16. C. T. M. Peeters, M. G. Netea, B. J. Kullberg, T. Thien, J. W. M. van dermeer. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology.1998; 94: 376-379.
17. Edwin K. Jackson. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL.Goodman and Gilman’s the pharmacological basis of therapeutics. 11thed.New York: McGraw-Hill. 2006: 789-821.
18. Wooley PH. Animal models of rheumatoid arthritis. Current Opinion in Rheumatology. 1991;3(3):407–420.
19. Byron H. Waksman, Carl M. Pearson, John T. Sharp. I.Studies of Arthritis and Other Lesions Induced in Rats by Injection of Mycobacterial Adjuvant. II.Evidence That the Disease Is a
Disseminated Immunologic Response to Exogenous Antigen. The Journal of Immunology. 1960; 85: 403 -417.
20. Laudanno OM, Cesolari JA. Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs. ActaGastroenterolLatinoam. 2006 Jun;36(2):76-80.
21. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung. 1986 Nov;36(11):1605-8.
22. Pearson C.M., Wood F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. General, clinical and pathological characteristics and modifying factors. Arthritis and Rheumatism. 1959;2:440-459.
23. B.B. Newbould. Chemotherapy Of Arthritis Induced in Rats by Mycobacterial Adjuvant. Brit.J.Pharmacol.1963; 21:127-136
24. Andreas J. Flammer, Isabella Sudano, Frank Hermann. Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis. Circulation. 2008;117:2262-2269.
25. C. T. M. Peeters, M. G. Netea, B. J. Kullberg, T. Thien, J. W. M. van dermeer. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology.1998; 94: 376-379.
26. RA Gomez, LL Norling, N Wilfong. Leukocytes synthesize angiotensinogen. Hypertension. 1993; 21: 470-475.
27. F Mindlen, R Nordaby, M Ruiz, A Zavala, Cardoba: L Guzman, F Martinez. et al. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. NEJM. Jan 20, 2000; 342:145-153.
28. Stella Brili,Dimitris Tousoulis,Charalambos Antoniades,Carmen Vasiliadou, Maria Karali, Nikos Papageorgiou. et al. Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation ofAorta: A Randomized Cross-Over Study. Journal of the American College of Cardiology. 2008; Vol 51, Issue 7: 742-749
2. Maya Buch. The etiology and pathogenesis of Rheumatoid Arthritis. Hospital Pharmacist. 2002;9:5-10.
3. Peter E. Lipsky. Rheumatoid arthritis. In: Fauci, Braunwald, Kasper, Hauser, Lango, Jaueson et al. Harrison’s Principles of Internal Medicine.17th ed. New York: McGraw-Hill. 2008: 2088-92.
4. Ruiz-Ortega, Marta, Lorenzo. Proinflammatory actions of angiotensins. Current Opinion in Nephrology & Hypertension.2001; 10(3): 321-329.
5. M. Ruiz-Ortega, O. Lorenzo, M. Rupérez. Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field. Hypertension. 2001; 38: 1382-1387.
6. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem Biophys Res Commun.1999; 257: 826-8.
7. Gunter Wolf, Ulrich Wenzel, Kevin D Burns. Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney International. 2002; 61: 1986–1995.
8. J R Lowe, J S Dixon, J A Guthrie. Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis. Ann Rheum Dis. 1986; 45: 921-924.
9. David A. Walsh, Takahiro Suzuki, Gregory A. Knock. AT1 receptor characteristics ofangiotensin analogue binding in human synovium. Br. J. Pharmacol.1994; 112: 435-442.
10. Martin MFR, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril a new treatment for rheumatoid arthritis? Lancet. 1984; 1: 1325-1328.
11. Bird HA, Le Gallez P, Dixon JS, Catalano MA, Traficante A, Liauw L, et al. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentropril; CGS-13945) in active rheumatoid arthritis. J Rheumatol. 1990; 17: 603–8.
12. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford). 2005; 44: 24–31.
13. Pearson C.M., Wood F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. General, clinical and pathological characteristics and modifying factors. Arthritis and Rheumatism. 1959;2:440-459.
14. Krenn V, Morawietz L, Haupl T. Grading of chronic synovitis- a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract. 2002;198(5):317-25.
15. Vogel HG. Adjuvant Arthritis in Rats. In Drug discovery & evaluation: Pharmacological assays. 3rded. New York: Springer – Verlag. 2008: 1162-1166.
16. C. T. M. Peeters, M. G. Netea, B. J. Kullberg, T. Thien, J. W. M. van dermeer. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology.1998; 94: 376-379.
17. Edwin K. Jackson. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL.Goodman and Gilman’s the pharmacological basis of therapeutics. 11thed.New York: McGraw-Hill. 2006: 789-821.
18. Wooley PH. Animal models of rheumatoid arthritis. Current Opinion in Rheumatology. 1991;3(3):407–420.
19. Byron H. Waksman, Carl M. Pearson, John T. Sharp. I.Studies of Arthritis and Other Lesions Induced in Rats by Injection of Mycobacterial Adjuvant. II.Evidence That the Disease Is a
Disseminated Immunologic Response to Exogenous Antigen. The Journal of Immunology. 1960; 85: 403 -417.
20. Laudanno OM, Cesolari JA. Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs. ActaGastroenterolLatinoam. 2006 Jun;36(2):76-80.
21. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung. 1986 Nov;36(11):1605-8.
22. Pearson C.M., Wood F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. General, clinical and pathological characteristics and modifying factors. Arthritis and Rheumatism. 1959;2:440-459.
23. B.B. Newbould. Chemotherapy Of Arthritis Induced in Rats by Mycobacterial Adjuvant. Brit.J.Pharmacol.1963; 21:127-136
24. Andreas J. Flammer, Isabella Sudano, Frank Hermann. Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis. Circulation. 2008;117:2262-2269.
25. C. T. M. Peeters, M. G. Netea, B. J. Kullberg, T. Thien, J. W. M. van dermeer. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology.1998; 94: 376-379.
26. RA Gomez, LL Norling, N Wilfong. Leukocytes synthesize angiotensinogen. Hypertension. 1993; 21: 470-475.
27. F Mindlen, R Nordaby, M Ruiz, A Zavala, Cardoba: L Guzman, F Martinez. et al. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. NEJM. Jan 20, 2000; 342:145-153.
28. Stella Brili,Dimitris Tousoulis,Charalambos Antoniades,Carmen Vasiliadou, Maria Karali, Nikos Papageorgiou. et al. Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation ofAorta: A Randomized Cross-Over Study. Journal of the American College of Cardiology. 2008; Vol 51, Issue 7: 742-749
Downloads
Published
2013-06-30
How to Cite
Munde, D. G. Y., & Pandit, D. P. R. (2013). Anti-inflammatory Effects of Ramipril In Experimentally Induced Rheumatoid Arthritis: Anti-inflammatory Effects of Ramipril. National Journal of Integrated Research in Medicine, 4(3), 1–7. https://doi.org/10.70284/njirm.v4i3.2170
Issue
Section
Original Articles
